In last trading session, TELA Bio, Inc. (NASDAQ:TELA) saw 957,775 shares changing hands. Company’s recent per share price level of $14.45 trading at -$3.83 or -20.96% at recent trade assigns it a market valuation of $164.73 Million. That current price of TELA’s stock is at a discount of -62.98% from its 52-week high price of $23.55 and is indicating a premium of 63.67% from its 52-week low price of $5.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 72.42 Million shares which gives us an average trading volume of 40.97 Million if we extend that period to 3-months.
For TELA Bio, Inc. (TELA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.59 in the current quarter.
TELA Bio, Inc. (NASDAQ:TELA) trade information
In the face of being in the red today for losing -21.18%, in the last five days TELA remained trading in the green while hitting it’s week-highest on Monday, Jun 22 when the stock touched $22.80- price level, adding 35.99% to its value on the day. TELA Bio, Inc.’s shares saw a change of 12.7% in year-to-date performance and have moved -35.45% in past 5-day. TELA Bio, Inc. (NASDAQ:TELA) showed a performance of 4.7% in past 30-days. Number of shares sold short was 92.38 Million shares which calculate 2.25 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $18.75 to the stock, which implies a rise of 29.76% to its current value. Analysts have been projecting $14 as a low price target for the stock while placing it at a high target of $24. It follows that stock’s current price would jump +66.09% in reaching the projected high whereas dropping to the targeted low would mean a loss of -3.11% for stock’s current value.
TELA Bio, Inc. (TELA) estimates and forecasts
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.86 Million for the same. And 4 analysts are in estimates of company making revenue of $3.68 Million in the next quarter that will end in September 01, 2020. Company posted $3.3 Million and $3.97 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -43.7% while estimating it to be -7.4% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 2.6% while estimates for its earnings growth in next 5 years are of 0%
TELA Bio, Inc. (NASDAQ:TELA)’s Major holders
Insiders are in possession of 4.1% of company’s total shares while institution are holding 75.52% percent of that, with stock having share float percentage of 78.75%. Investors also watch the number of corporate investors in a company very closely, which is 30 institutions for TELA Bio, Inc. that are currently holding shares of the company. Orbimed Advisors LLC. is the top institutional holder at TELA for having 3.03 Million shares of worth $23.68 Million. And as of March 30, 2020, it was holding 26.54% of the company’s outstanding shares.
The second largest institutional holder is RTW Investments LP, which was holding about 1.14 Million shares on March 30, 2020. The number of shares represents firm’s hold over 9.99% of outstanding shares, having a total worth of $8.91 Million.
On the other hand, Federated Kaufmann Small Cap Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of January 30, 2020, the former fund manager was holding 400000 shares of worth $5.96 Million or 3.51% of the total outstanding shares. The later fund manager was in possession of 29.23 Thousand shares on March 30, 2020, making its stake of worth around $228.57 Thousand in the company or a holder of 0.26% of company’s stock.